NCT05185544

Brief Summary

Combining genomics and imageomics to predict the sensitivity of neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2022

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 18, 2021

Completed
14 days until next milestone

Study Start

First participant enrolled

January 1, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

January 11, 2022

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

January 11, 2022

Status Verified

December 1, 2021

Enrollment Period

3 years

First QC Date

December 18, 2021

Last Update Submit

January 5, 2022

Conditions

Sensitivity

Outcome Measures

Primary Outcomes (1)

  • Tumor Regression Grade

    1-2 Weeks after enrollment (after Surgery)

Study Arms (1)

neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

Other: Neoadjuvant pemetrexed and cisplatin chemotherapy

Interventions

Neoadjuvant pemetrexed and cisplatin chemotherapyOTHER

neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

You may qualify if:

  • \. Aged between 18 and 75 years;
  • \. Lung adenocarcinoma;
  • \. The patient is able to receive neoadjuvant pemetrexed and cisplatin chemotherapy
  • The patient is able to understand and comply with the study and has provided written informed consent.

You may not qualify if:

  • \. Patients with a history of lung surgery;
  • \. Postoperative pathology showed non-primary lung cancer;
  • \. Patients with a history of other tumors;
  • \. Patients with severe complications (coronary heart disease, valvular heart disease, end-stage renal disease, severe liver cirrhosis);
  • \. Unable to cooperate with the researchers because of dementia or cognitive decline
  • \. Other situations that are not in conformity with the standards and requirements of this trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hypersensitivity

Condition Hierarchy (Ancestors)

Immune System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 18, 2021

First Posted

January 11, 2022

Study Start

January 1, 2022

Primary Completion

December 31, 2024

Study Completion

December 31, 2024

Last Updated

January 11, 2022

Record last verified: 2021-12